Immune thrombocytopenia triggered by dostarlimab in a patient with endometrial carcinoma: first reported case

Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for various malignancies, but they are associated with a range of immunerelated adverse events, including rare hematological complications. Immune thrombocytopenia (ITP) has been reported with other antiPD1 agents such as n...

Full description

Bibliographic Details

Main Authors:	Adolfo Fernández-Sánchez, Pablo García-Jaén, Carlos Puerta-Vázquez, M. Belén Pazmiño-Zambrano, Pablo Reguera-Puertas, José Ramón González-Porras, José María Bastida
Format:	Artigo
Language:	Inglês
Published:	Taylor & Francis Group 2026-12-01
Series:	Platelets
Subjects:	Dostarlimab endometrial carcinoma immune thrombocytopenia immune-related adverse events PD-1 inhibitors romiplostim
Online Access:	https://www.tandfonline.com/doi/10.1080/09537104.2025.2601056
Tags:	Add Tag No Tags, Be the first to tag this record!